Technology, pharmacology, and clinical outcomes of sirolimus coated balloons for peripheral arterial interventions

Ruttiros Khonkarn; Pranvera  Ramadani; Sheng Qi; Tariq  Ali; Miltiadis  Krokidis

doi:10.1080/17434440.2025.2574364

Technology, pharmacology, and clinical outcomes of sirolimus coated balloons for peripheral arterial interventions

Ruttiros Khonkarn
, Pranvera Ramadani
, Sheng Qi
, Tariq Ali
, Miltiadis Krokidis

Research output: Contribution to journal › Review article › peer-review

Abstract

Introduction: Peripheral arterial intervention is a rapidly evolving field with a significant impact on an aging population.

Areas covered: Treatment concepts evolve rapidly, with new therapies providing sustainable and cost-effective solutions for complex patients.

Expert opinion: Metal stenting has been replaced by the ‘leave-nothing-behind’ approach, and plain balloon angioplasty devices have been replaced by drug-coated balloons (DCBs). While paclitaxel was initially used, sirolimus has more recently shown promising outcomes. This review article provides an overview of the technology and pharmacology behind sirolimus-coated balloons (SRL-DCB) and presents existing clinical evidence of their use.

Original language	English
Pages (from-to)	1369-1378
Number of pages	10
Journal	Expert Review of Medical Devices
Volume	22
Issue number	12
Early online date	11 Oct 2025
DOIs	https://doi.org/10.1080/17434440.2025.2574364
Publication status	Published - Dec 2025

Keywords

Peripheral Vascular Diseases
Drug-coated balloons
Restenosis
sirolimus
restenosis
Peripheral vascular disease
drug-coated balloons

Access to Document

10.1080/17434440.2025.2574364

Cite this

@article{dda6feaad4674400982011e1f53038a7,

title = "Technology, pharmacology, and clinical outcomes of sirolimus coated balloons for peripheral arterial interventions",

abstract = "Introduction: Peripheral arterial intervention is a rapidly evolving field with a significant impact on an aging population. Areas covered: Treatment concepts evolve rapidly, with new therapies providing sustainable and cost-effective solutions for complex patients. Expert opinion: Metal stenting has been replaced by the {\textquoteleft}leave-nothing-behind{\textquoteright} approach, and plain balloon angioplasty devices have been replaced by drug-coated balloons (DCBs). While paclitaxel was initially used, sirolimus has more recently shown promising outcomes. This review article provides an overview of the technology and pharmacology behind sirolimus-coated balloons (SRL-DCB) and presents existing clinical evidence of their use.",

keywords = "Peripheral Vascular Diseases, Drug-coated balloons, Restenosis, sirolimus, restenosis, Peripheral vascular disease, drug-coated balloons",

author = "Ruttiros Khonkarn and Pranvera Ramadani and Sheng Qi and Tariq Ali and Miltiadis Krokidis",

year = "2025",

month = dec,

doi = "10.1080/17434440.2025.2574364",

language = "English",

volume = "22",

pages = "1369--1378",

journal = "Expert Review of Medical Devices",

issn = "1745-2422",

publisher = "Taylor and Francis",

number = "12",

}

TY - JOUR

T1 - Technology, pharmacology, and clinical outcomes of sirolimus coated balloons for peripheral arterial interventions

AU - Khonkarn, Ruttiros

AU - Ramadani, Pranvera

AU - Qi, Sheng

AU - Ali, Tariq

AU - Krokidis, Miltiadis

PY - 2025/12

Y1 - 2025/12

N2 - Introduction: Peripheral arterial intervention is a rapidly evolving field with a significant impact on an aging population. Areas covered: Treatment concepts evolve rapidly, with new therapies providing sustainable and cost-effective solutions for complex patients. Expert opinion: Metal stenting has been replaced by the ‘leave-nothing-behind’ approach, and plain balloon angioplasty devices have been replaced by drug-coated balloons (DCBs). While paclitaxel was initially used, sirolimus has more recently shown promising outcomes. This review article provides an overview of the technology and pharmacology behind sirolimus-coated balloons (SRL-DCB) and presents existing clinical evidence of their use.

AB - Introduction: Peripheral arterial intervention is a rapidly evolving field with a significant impact on an aging population. Areas covered: Treatment concepts evolve rapidly, with new therapies providing sustainable and cost-effective solutions for complex patients. Expert opinion: Metal stenting has been replaced by the ‘leave-nothing-behind’ approach, and plain balloon angioplasty devices have been replaced by drug-coated balloons (DCBs). While paclitaxel was initially used, sirolimus has more recently shown promising outcomes. This review article provides an overview of the technology and pharmacology behind sirolimus-coated balloons (SRL-DCB) and presents existing clinical evidence of their use.

KW - Peripheral Vascular Diseases

KW - Drug-coated balloons

KW - Restenosis

KW - sirolimus

KW - restenosis

KW - Peripheral vascular disease

KW - drug-coated balloons

UR - https://www.scopus.com/pages/publications/105019265259

U2 - 10.1080/17434440.2025.2574364

DO - 10.1080/17434440.2025.2574364

M3 - Review article

SN - 1745-2422

VL - 22

SP - 1369

EP - 1378

JO - Expert Review of Medical Devices

JF - Expert Review of Medical Devices

IS - 12

ER -

Technology, pharmacology, and clinical outcomes of sirolimus coated balloons for peripheral arterial interventions

Abstract

Keywords

Access to Document

Other files and links

Embargoed Document

Cite this